Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Corporate Update (October 2019)

15 slides from Reata Pharmaceuticals's corporate update, Oct 15, 2019

  1. Slide 1: Management call to discuss positive topline pivotal MOXIe data

    Management call to discuss Positive topline pivotal MOXIE Data Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement

  3. Slide 3: Friedreich's Ataxia Overview

    Friedreich’s Ataxia Overview 1 Parkinson MH, et al., J Neurochem. 2013; 52Santos R, et al., Antioxid Redox Signal. 2010; 3Klockgether T, et al., Brain. 1998 Estimated Prevalence ~5,000 in US ~22,000 Globally Friedreich’s ataxia (FA) is a rare, debilitating, life-shortening, neuromuscular disorder Pa

  4. Slide 4: Mitochondrial Dysfunction Leads to Impaired Neurological Function in FA

    Mitochondrial Dysfunction Leads to Impaired Neurological Function in FA FA is caused by mutations in the frataxin gene, resulting in impaired mitochondrial function, Nrf2 suppression, neuroinflammation, and neurodegeneration Drinkard, et al., Arch Phys Med Rehabil (2010) Mitochondrial Function (Peak

  5. Slide 5: Study Rationale: Omaveloxolone Improves Mitochondrial Function

    Study Rationale: Omaveloxolone (Omav) Improves Mitochondrial Function Omav restored mitochondrial function in FA patient samples in vitro Omav improved neurological function in patients with FA in MOXIe Part 1 Omav Restored Mitochondrial Function in FA Patient Samples MOXIe Part 1: Omav Improved Neu

  6. Slide 6: MOXIe Part 2: Pivotal Study Design

    MOXIe Part 2: Pivotal Study Design International, double-blind, placebo-controlled, randomized, registrational trial Largest global interventional study in patients with FA Enrolled a wide and representative range of patients with FA Baseline mFARS: 20 to 80 Age: 16 to 40 years Patients randomized 1

  7. Slide 7: mFARS: Physician-Assessed Neurological Exam that Tracks Progression of FA

    mFARS: Physician-Assessed Neurological Exam that Tracks Progression of FA mFARS has four sections that are considered clinically meaningful In FA patients, mFARS worsens (increases) on average one to two points annually FDA provided guidance that mFARS is an approvable endpoint in FA Patel et al., A

  8. Slide 8: Omav Treatment Met Primary Endpoint of Study

    Omav Treatment Met Primary Endpoint of Study Omav treatment significantly improved mFARS by 2.40 points relative to placebo in the primary analysis population (n=82; p=0.014) In the all randomized population, with inclusion of pes cavus patients, Omav treatment improved mFARS by 1.93 points relative

  9. Slide 9: mFARS Improved Over Time

    mFARS Improved Over Time Worsened Improved -1.55 pts +0.85 pts

  10. Slide 10: Omav Improved Several Secondary Endpoints

    Omav Improved Several Secondary Endpoints Improvements observed in Patient Global Impression of Change (PGIC) Primary analysis population (n=82; p=0.125) All randomized population (n=103; p=0.028) Patient-reported PGIC correlated with physician-assessed changes in mFARS (p<0.001) Activities of Daily

  11. Slide 11: Summary of Discontinuations and Adverse Events

    Summary of Discontinuations and Adverse Events AEs generally mild to moderate in intensity 4 (8%) Omav patients and 2 (4%) placebo patients discontinued study due to AEs Three additional Omav patients discontinued by withdrawal of consent 98% of eligible patients elected to enroll in MOXIe Part 3 ex

  12. Slide 12: Summary of Serious Adverse Events

    Summary of Serious Adverse Events Low rate of serious AEs (SAEs) SAEs reported in 3 (6%) Omav patients and 3 (6%) placebo patients while receiving study drug Two additional Omav patients reported SAEs approximately 2 weeks after receiving final dose No safety signals and SAEs were sporadic and gener

  13. Slide 13: Summary and Next Steps

    Summary and Next Steps Reata believes that the MOXIe data provide evidence that Omav provides a clinically meaningful benefit to patients with FA Potential for Omav to be first approved treatment for FA Working closely with the Friedreich’s Ataxia Research Alliance (FARA) to communicate with the pat

  14. Slide 14: Omav Pharmacology May Be Applicable to Broad Set of Neurodegenerative Diseases

    Omav Pharmacology May Be Applicable to Broad Set of Neurodegenerative Diseases MOXIe results provide proof of concept for use of Omav in other neurodegenerative diseases Mitochondrial dysfunction and neuroinflammation are common features of FA and other neurodegenerative diseases Omav and analogs ha

  15. Slide 15: Reata Pharmaceuticals

    s°s REATA | aaa ee PHARMACEUTICALS

Reata Pharmaceuticals — Corporate Update (October 2019) on 6ix